« Return to News | CROs/Service Providers

ICON, QPS Receive Industry Accreditations

Friday, September 18, 2009 07:14 AM

Dublin, Ireland-based contract research organization (CRO) ICON received industry accreditations for three of its laboratories in the UK and Singapore, and Newark, Del.-based QPS received a Good Laboratory Practice (GLP) certificate for its Taiwan operations.

ICON’s bioanalytical laboratory in Manchester, UK, received GCP and GLP accreditation from the Medicines and Healthcare products Regulatory Agency, while the CRO’s clinical pathology laboratory in Manchester received GCP accreditation. ICON now has two GLP-accredited bioanalytical laboratories, following the company’s acquisition of U.S.-based Prevalere Life Sciences in November 2008.

The CRO’s central laboratory in Singapore was awarded the Level I Certificate of Traceability by the National Glycohemoglobin Standardisation Program.

QPS was awarded a GLP-laboratory certification for QPS Taiwan, the company’s Asian operation. According to QPS, the certification, given by the Department of Health (DOH), Executive Yuan, R.O.C. (Taiwan), is the first and only GLP-laboratory certification given by the DOH, Taiwan, for bioanalytical services supporting preclinical and clinical research.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.